Functional Inhibition of VEGF and EGFR Suppressors in Cancer Treatment

Author(s): Anuraj Nayarisseri, Sanjeev Kumar Singh

Journal Name: Current Topics in Medicinal Chemistry

Volume 19 , Issue 3 , 2019

Become EABM
Become Reviewer
Call for Editor

Tabernero, J. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol. Cancer Res., 2007, 5(3), 203-220. []. [PMID: 17374728].
Pabla, B.; Bissonnette, M.; Konda, V.J. Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention. World J. Clin. Oncol., 2015, 6(5), 133-141. []. [PMID: 26468449].
Lurje, G.; Lenz, H-J. EGFR signaling and drug discovery. Oncology, 2009, 77(6), 400-410. []. [PMID: 20130423].
Seshacharyulu, P.; Ponnusamy, M.P.; Haridas, D.; Jain, M.; Ganti, A.K.; Batra, S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets, 2012, 16(1), 15-31. []. [PMID: 22239438].
Gudala, S.; Khan, U.; Kanungo, N.; Bandaru, S.; Hussain, T.; Parihar, M.; Nayarisseri, A.; Mundluru, H.P. Identification and pharmacological analysis of high efficacy small molecule inhibitors of EGF-EGFR interactions in clinical treatment of non-small cell lung carcinoma: A computational approach. Asian Pac. J. Cancer Prev., 2015, 16(18), 8191-8196. []. [PMID: 26745059].
Gross-Goupil, M. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin. Med. Insights Oncol., 2013, 7, S10594.
Sharma, K. Structure base Virtual screening for the identification of high affinity compounds as potent VEGFR2 inhibitors for the treatment of renal cell carcinoma. Curr. Top. Med. Chem., 2018.
Kilfoy, B.A.; Zheng, T.; Holford, T.R.; Han, X.; Ward, M.H.; Sjodin, A.; Zhang, Y.; Bai, Y.; Zhu, C.; Guo, G.L.; Rothman, N.; Zhang, Y. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control, 2009, 20(5), 525-531. []. [PMID: 19016336].
Dunna, N.R.; Kandula, V.; Girdhar, A.; Pudutha, A.; Hussain, T.; Bandaru, S.; Nayarisseri, A. High affinity pharmacological profiling of dual inhibitors targeting RET and VEGFR2 in inhibition of kinase and angiogeneis events in medullary thyroid carcinoma. Asian Pac. J. Cancer Prev., 2015, 16(16), 7089-7095. []. [PMID: 26514495].
Nayarisseri, A. In silico investigations on HSP90 and its inhibition for the therapeutic prevention of breast cancer. J. Pharm. Res., 2013, 7(2), 150-156. [].
Vuree, S. Pharmacogenomics of drug resistance in Breast Cancer Resistance Protein (BCRP) and its mutated variants. J. Pharm. Res., 2013, 6(7), 791-798. [].
Patidar, K.; Deshmukh, A.; Bandaru, S.; Lakkaraju, C.; Girdhar, A.; Vr, G.; Banerjee, T.; Nayarisseri, A.; Singh, S.K. Virtual screening approaches in identification of bioactive compounds akin to delphinidin as potential HER2 inhibitors for the treatment of breast cancer. Asian Pac. J. Cancer Prev., 2016, 17(4), 2291-2295. []. [PMID: 27221932].
Praseetha, S.; Bandaru, S.; Nayarisseri, A.; Sureshkumar, S. Pharmacological analysis of vorinostat analogues as potential anti-tumor agents targeting human histone deacetylases: An epigenetic treatment stratagem for cancers. Asian Pac. J. Cancer Prev., 2016, 17(3), 1571-1576. []. [PMID: 27039807].
Sharda, S.; Sarmandal, P.; Cherukommu, S.; Dindhoria, K.; Yadav, M.; Bandaru, S.; Sharma, A.; Sakhi, A.; Vyas, T.; Hussain, T.; Nayarisseri, A.; Singh, S.K. A virtual screening approach for the identification of high affinity small molecules targeting BCR-ABL1 inhibitors for the treatment of chronic myeloid leukemia. Curr. Top. Med. Chem., 2017, 17(26), 2989-2996. []. [PMID: 28828991].
Nasr, A.B.; Ponnala, D.; Sagurthi, S.R.; Kattamuri, R.K.; Marri, V.K.; Gudala, S.; Lakkaraju, C.; Bandaru, S.; Nayarisseri, A. Molecular Docking studies of FKBP12-mTOR inhibitors using binding predictions. Bioinformation, 2015, 11(6), 307-315. []. [PMID: 26229292].
Sinha, K.; Majhi, M.; Thakur, G.; Patidar, K.; Sweta, J.; Hussain, T.; Nayarisseri, A.; Singh, S.K. Computer aided Drug Designing for the identification of high affinity small molecule targeting CD20 for the clinical treatment of Chronic Lymphocytic Leukemia (CLL). Curr. Top. Med. Chem., 2018, 18(29), 2527-2542. []. [PMID: 30526461].
Khandelwal, R.; Chauhan, A.P.S.; Bilawat, S.; Gandhe, A.; Hussain, T.; Hood, E.A.; Nayarisseri, A.; Singh, S.K. Structure-based virtual screening for the identification of high affinity small molecule towards STAT3 for the clinical treatment of Osteosarcoma. Curr. Top. Med. Chem., 2018, 18(29), 2511-2526. []. [PMID: 30430945].
Bandaru, S.; Sumithnath, T.G.; Sharda, S.; Lakhotia, S.; Sharma, A.; Jain, A.; Hussain, T.; Nayarisseri, A.; Singh, S.K. Helix-coil transition signatures B-Raf V600E mutation and virtual screening for inhibitors directed against mutant B-Raf. Curr. Drug Metab., 2017, 18(6), 527-534. []. [PMID: 28472910].
Rao, D.M. Comparative modeling of methylentetrahydrofolate reductase (MTHFR) enzyme and its mutational assessment: in silico approach. Int. J. Bioinform. Res., 2010, 2(1), 5-9. [].
Sinha, C.; Nischal, A.; Bandaru, S.; Kasera, P.; Rajput, A.; Nayarisseri, A.; Khattri, S. An in silico approach for identification of novel inhibitors as a potential therapeutics targeting HIV-1 viral infectivity factor. Curr. Top. Med. Chem., 2015, 15(1), 65-72. [ 10.2174/1568026615666150112114337]. [PMID: 25579575].

promotion: free to download

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Published on: 28 March, 2019
Page: [178 - 179]
Pages: 2
DOI: 10.2174/156802661903190328155731

Article Metrics

PDF: 47